Thursday July 12, 2:00 pm Eastern Time
Press Release
SOURCE: Genaissance Pharmaceuticals, Inc.
Genaissance Pharmaceuticals, Inc. Sponsors Conference Call To Discuss
Science Publication
NEW HAVEN, Conn., July 12 /PRNewswire/ -- Genaissance Pharmaceuticals (Nasdaq: GNSC - news), will conduct a
conference call to discuss the significance of its paper titled ``Haplotype Variation and Linkage Disequilibrium in 313 Human
Genes'' which appears in the July 13th issue of Science:
(Logo: newscom.com
Thursday, July 12, 2001
4:30 p.m. Eastern
To participate in this call,
dial: 913-981-5571
confirmation code: 427557
shortly before 4:30 p.m. Eastern
To reserve a line,
please call Rhonda Chiger at Nexus Communications Group, LLC
917-322-2569.
A replay of the call will be available from 7:30 p.m. Eastern through midnight Tuesday, July 17th. The replay number is
719-457-0820, confirmation code 427557.
Genaissance Pharmaceuticals, Inc. is the world leader in the study of human gene variation and is pioneering its application to
the development of personalized medicines. The Company discovers genetic markers (haplotypes) that are predictive of drug
efficacy and safety, and markets its technology to the pharmaceutical industry as a complete solution for improving the
development, marketing and prescribing of drugs. Moving from discovery to commercial application, Genaissance has launched
the largest prospective clinical trial ever conducted with the goal of allowing physicians to personalize prescriptions based on
the DNA of the patient. Genaissance is located in Science Park in New Haven, Connecticut. Please visit
genaissance.com for additional information.
SOURCE: Genaissance Pharmaceuticals, Inc. |
